MRFF Funding Opportunities

Date posted 7 September 2020

Closing date varies

Originally posted by Research Australia. View the original article here. 

Several funding opportunities are currently available under the MRFF, seeking to address a range of different diseases and issues in different health settings. They are presented in order of application closing date below.

Open for application now

COVID-19 Clinical Trials

$25 million is available for clinical trials to investigate effective mechanisms for the prevention and/or treatment of COVID-19 or its symptoms. Research will be conducted over three years and is expected to commence from early 2021. Applications for the grant program are to be made to the NHMRC and will close on 23 September 2020 (minimum data in Sapphire required by 9 September). Further information is available here.

Brain Cancer Survivorship

$3 million is available for grants supporting research on brain cancer survivorship through the Brain Cancer Mission to support new approaches and technologies to improve communications between brain cancer survivors, their families, carers and health care professionals. It will also target research into how information technologies and platforms can reduce physical, psychosocial and economic harm to people with brain cancer, their families and carers. Applications are now open and close on 20 October. More information is available here.

Primary Care Research

$4.8 million is available for primary health care research under the MRFF’s Translation theme, to improve health outcomes, raise the standard of clinical care and practice, support health system improvement in primary care, and/or improve primary health care policy. Administered by the NHMRC, minimum data is due by 28 October. More information is available here.

Medicinal Cannabis for cancer patients

$3 million is available for research into medicinal cannabis for managing pain, symptoms and side effects for cancer patients. Funding is through the MRFF’s Emerging Priorities and Consumer Driven Research Initiative. Applications are administered by the NHMRC and minimum data is due by 28 October. More information is available here.


The Emerging Priorities and Consumer Driven Research – 2020 Silicosis Research Grant Opportunity will support the investigation of evidence-based prevention and treatment options for individuals at risk of, or suffering from, accelerated silicosis caused by engineered stone. $4.5 million is available with applications administered by the NHMRC and minimum data due by 28 October. More information is available here.

Million Minds Mission

The Million Minds Mission 2020 Mental Health Research Grant Opportunity will support research into the following mental health priority areas: new mechanisms for early identification and prevention amongst children and adolescents; treatments for those with treatment resistant or treatment refractory mental health conditions; initiatives to address the physical health of individuals with mental illness; and mechanisms to support access to treatment. $24 million is available. Applications for funding are now open, with minimum data due to be lodged with the NHMRC by 28 October. More information is available here.

2020 Rare Cancers, Rare Diseases & Unmet Need Grants

Applications are sought for clinical trials that:

    • provide new opportunities for clinical trial participation for Australians with medical conditions with limited effective treatment options.
    • address under-researched health priorities and conditions, such as rare cancers and rare diseases.
    • Deploy innovative trial designs and recruitment strategies to provide high-quality evidence of the efficacy of new health treatments, drugs and devices.
    • involve purposeful health service engagement to improve the translation of research into practice and improve outcomes for patients.
    • Implement new health treatments, drugs and devices to improve health and wellbeing.

Applications for funding are now open, with minimum data due to be lodged with the NHMRC by 28 October. $25 million is available. More information is available here.

International Clinical Trials

The 2020 International Clinical Trial Collaborations grants support Australian involvement in international collaborative investigator-initiated clinical trials.

The anticipated outcomes of the research are

    • increased Australian leadership of, or participation in, international collaborative investigator-initiated clinical trials
    • high quality evidence to inform uptake of effective health treatments, drugs and devices to improve health practice and outcomes for patients
    • increased opportunities for patients to access novel treatments and therapies
    • growth in the capacity of Australia’s clinical trials workforce.

$25.2 million will be available over the next two financial years. This grant opportunity is being administered by NHMRC, and minimum data is due by 28 October. Further information is available here.

Clinical Trials and Cohort Studies

$70 million is available under the Clinical Trials and Cohort Studies Grant scheme for high-quality clinical trials and cohort studies of any size that address important gaps in knowledge, leading to relevant and implementable findings for the benefit of human health. This grant opportunity is open to research proposals for clinical trials and/or cohort studies of any size – that is, they may be large or small clinical trials or cohort studies.

Applications are administered by the NHMRC and minimum information, which was originally required by 1 April, is  now required by 4 November 2020. More information is available on the NHMRC website.

SARS CoV-2 Vaccine

The Australian Government is providing $13.6 million through an open competitive grant opportunity to support promising COVID-19 vaccine development projects in 2020-21. The grant opportunity will be open between 15 June 2020 and 15 March 2021, with expressions of interest assessed from 15 July 2020, 11 November 2020 and 10 March 2021. More information is available on the NHMRC website.

Read more via Research Australia.


News & opinion

Member Directory